Adma Biologics, INC 10-Q quarterly reports

ADMA Biologics announced a 2.0% increase in total revenues for Q2 2026, driven by significant ASCENIV sales growth, alongside improved gross margins.

ADMA Biologics reports strong Q1 2026 net income of $45.3 million, driven by ASCENIV growth and improved manufacturing yields.

ADMA Biologics reported a 12% revenue increase in Q3 2025, driven by ASCENIV sales, alongside a significant debt refinancing and share repurchase program.

ADMA Biologics reported significant revenue and gross profit increases for Q2 2025, driven by strong ASCENIV sales and operational efficiencies, while also refinancing its senior credit facility.

ADMA Biologics reports a 40% increase in revenue for Q1 2025, driven by strong sales of ASCENIV, and announces FDA approval of its yield enhancement production process.

ADMA Biologics reports a significant increase in revenue and net income for the third quarter of 2024, driven by strong sales of its immunoglobulin products and improved manufacturing efficiencies.

ADMA Biologics reports a significant increase in revenue and a return to profitability in the second quarter of 2024, driven by strong sales of its immunoglobulin products.

ADMA Biologics reports a profitable first quarter of 2024, driven by increased sales of its immunoglobulin products and improved gross margins.